Trending Stock News

EPS for Autodesk, Inc. (ADSK) Expected At $-0.18; Biocryst Pharmaceuticals (BCRX) SI Decreased By 2.37%

Autodesk, Inc. (NASDAQ:ADSK) Logo

Analysts expect Autodesk, Inc. (NASDAQ:ADSK) to report $-0.18 EPS on May, 24 after the close.They anticipate $0.25 EPS change or 58.14% from last quarter’s $-0.43 EPS. After having $-0.36 EPS previously, Autodesk, Inc.’s analysts see -50.00% EPS growth. The stock increased 0.43% or $0.59 during the last trading session, reaching $136.52. About 1.29M shares traded. Autodesk, Inc. (NASDAQ:ADSK) has risen 50.18% since May 18, 2017 and is uptrending. It has outperformed by 38.63% the S&P500.

Biocryst Pharmaceuticals Inc (NASDAQ:BCRX) had a decrease of 2.37% in short interest. BCRX’s SI was 10.80M shares in May as released by FINRA. Its down 2.37% from 11.06M shares previously. With 831,200 avg volume, 13 days are for Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)’s short sellers to cover BCRX’s short positions. The SI to Biocryst Pharmaceuticals Inc’s float is 15.16%. The stock decreased 1.34% or $0.08 during the last trading session, reaching $5.9. About 1.39 million shares traded or 68.94% up from the average. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has declined 43.31% since May 18, 2017 and is downtrending. It has underperformed by 54.86% the S&P500.

Investors sentiment decreased to 1.08 in Q4 2017. Its down 0.34, from 1.42 in 2017Q3. It dropped, as 46 investors sold Autodesk, Inc. shares while 171 reduced holdings. 84 funds opened positions while 151 raised stakes. 204.78 million shares or 0.77% less from 206.38 million shares in 2017Q3 were reported. Zurcher Kantonalbank (Zurich Cantonalbank) reported 123,971 shares stake. The New York-based Pinebridge Investments L P has invested 0.05% in Autodesk, Inc. (NASDAQ:ADSK). Livforsakringsbolaget Skandia Omsesidigt holds 0.03% or 2,985 shares in its portfolio. Ftb Advisors reported 0% of its portfolio in Autodesk, Inc. (NASDAQ:ADSK). Nomura stated it has 323,232 shares. Tci Wealth reported 0.01% stake. Domini Impact Invests Limited Liability Corporation stated it has 5.16% of its portfolio in Autodesk, Inc. (NASDAQ:ADSK). Nuveen Asset Mgmt Lc holds 0.14% or 202,039 shares. Advisor Prns Ltd Limited Liability Company invested 0.13% in Autodesk, Inc. (NASDAQ:ADSK). Liberty Mutual Grp Asset Mgmt has invested 0.03% in Autodesk, Inc. (NASDAQ:ADSK). Moreover, Brandywine Managers Ltd Com has 0.21% invested in Autodesk, Inc. (NASDAQ:ADSK) for 7,210 shares. Savings Bank Of Nova Scotia stated it has 34,251 shares or 0.02% of all its holdings. Moreover, Cookson Peirce & Inc has 0.23% invested in Autodesk, Inc. (NASDAQ:ADSK). Balyasny Asset Mgmt Ltd Llc owns 634,807 shares. Eastern Bancshares accumulated 2,087 shares.

Since March 7, 2018, it had 0 buys, and 8 insider sales for $6.09 million activity. BEVERIDGE CRAWFORD W also sold $199,665 worth of Autodesk, Inc. (NASDAQ:ADSK) shares. On Thursday, March 29 Anagnost Andrew sold $2.57 million worth of Autodesk, Inc. (NASDAQ:ADSK) or 20,499 shares. 2,746 shares valued at $350,692 were sold by Underwood Paul D. on Wednesday, March 28. $2.53M worth of Autodesk, Inc. (NASDAQ:ADSK) shares were sold by Blum Steven M. Di Fronzo Pascal W had sold 388 shares worth $48,329.

Among 27 analysts covering Autodesk Inc. (NASDAQ:ADSK), 18 have Buy rating, 3 Sell and 6 Hold. Therefore 67% are positive. Autodesk Inc. had 125 analyst reports since August 4, 2015 according to SRatingsIntel. OTR Global downgraded Autodesk, Inc. (NASDAQ:ADSK) on Friday, October 30 to “Mixed” rating. The firm has “Neutral” rating by Wedbush given on Wednesday, November 29. The firm has “Outperform” rating by RBC Capital Markets given on Friday, May 19. The company was maintained on Thursday, February 4 by RBC Capital Markets. RBC Capital Markets maintained the stock with “Sector Perform” rating in Friday, February 26 report. Cowen & Co maintained it with “Outperform” rating and $71 target in Friday, August 26 report. The firm has “Buy” rating by Cowen & Co given on Wednesday, March 7. OTR Global downgraded the stock to “Mixed” rating in Thursday, August 3 report. RBC Capital Markets maintained the shares of ADSK in report on Sunday, September 3 with “Buy” rating. The stock of Autodesk, Inc. (NASDAQ:ADSK) earned “Outperform” rating by Credit Suisse on Friday, August 25.

More notable recent Autodesk, Inc. (NASDAQ:ADSK) news were published by: Streetinsider.com which released: “Autodesk (ADSK) PT Raised to $160 at Morgan Stanley Amid Confidence in Billings Growth” on May 15, 2018, also Fool.com with their article: “General Motors and Autodesk Ally to Bring Driverless Electric Vehicle Future Closer” published on May 07, 2018, Streetinsider.com published: “Autodesk (ADSK) PT Raised to $150 at Deutsche Bank on 1Q Preview; ‘Expect ADSK to Exceed High End Revenue …” on May 14, 2018. More interesting news about Autodesk, Inc. (NASDAQ:ADSK) were released by: Streetinsider.com and their article: “Tiger Global’s 13F Shows New Stake in Twitter (TWTR), Mercado (MELI), Increases Stake in Amazon (AMZN) (more…)” published on May 15, 2018 as well as Streetinsider.com‘s news article titled: “JANA Shows New Stakes in Apple (AAPL), Boston Scientific (BSX), Dropbox (DBX), iQIYI (IQ) (more..) -13F” with publication date: May 15, 2018.

Autodesk, Inc. operates as a design software and services firm worldwide. The company has market cap of $29.91 billion. It operates through Architecture, Engineering, and Construction; Manufacturing; Platform Solutions and Emerging Business; and Media and Entertainment divisions. It currently has negative earnings. The firm offers AutoCAD, a professional design, drafting, detailing, and visualization software; and AutoCAD LT, a professional drafting and detailing software; Maya and 3ds Max software products that offer 3D modeling, animation, effects, rendering, and compositing solutions; and Revit software for building information modeling.

BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company has market cap of $582.43 million. The firm markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU. It currently has negative earnings. It also has various ongoing development programs, including BCX7353 and second generation oral inhibitors of plasma kallikrein for hereditary angioedema; and galidesivir, a broad spectrum viral RNA polymerase inhibitor that is indicated to treat filoviruses, as well as forodesine, an oral purine nucleoside phosphorylase inhibitor for use in oncology.

More news for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) were recently published by: Nasdaq.com, which released: “New Research: Key Drivers of Growth for OFG, Oshkosh, Vishay Precision Group, Endocyte, BioCryst Pharmaceuticals …” on April 26, 2018. Nasdaq.com‘s article titled: “BioCryst to Announce First Quarter 2018 Financial Results on May 8” and published on April 26, 2018 is yet another important article.

Autodesk, Inc. (NASDAQ:ADSK) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *